Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) shares were up 4% during mid-day trading on Tuesday . The company traded as high as $5.35 and last traded at $5.25. Approximately 113,542 shares were traded during trading, a decline of 92% from the average daily volume of 1,391,078 shares. The stock had previously closed at $5.05.
Dominari Stock Down 3.3%
The stock's 50 day moving average price is $4.67 and its 200-day moving average price is $3.57. The stock has a market capitalization of $84.79 million, a PE ratio of -1.50 and a beta of 0.59.
Dominari (NASDAQ:DOMH - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $0.20 EPS for the quarter. The business had revenue of $6.56 million during the quarter. Dominari had a negative net margin of 180.22% and a negative return on equity of 32.89%.
Hedge Funds Weigh In On Dominari
A hedge fund recently raised its stake in Dominari stock. Renaissance Technologies LLC grew its stake in Dominari Holdings Inc. (NASDAQ:DOMH - Free Report) by 20.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 56,326 shares of the company's stock after purchasing an additional 9,400 shares during the period. Renaissance Technologies LLC owned about 0.89% of Dominari worth $55,000 at the end of the most recent quarter. Institutional investors and hedge funds own 42.48% of the company's stock.
Dominari Company Profile
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Further Reading
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
